Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries

László Szilberhorn*, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen van Molken, Rositsa Koleva-Kolarova, Apostolos Tsiachristas, Sarah Wordsworth, Balázs Nagy

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
12 Downloads (Pure)

Abstract

Background:
Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment.

Materials & Methods:
A diabetes model was adapted to Hungary, the Netherlands, and the UK to analyse the cost–effectiveness and budget impact of different screening strategies for MODY with 20 years time horizon.

Results:
Compared with no screening, screening with the MODY calculator then genetic testing is considered cost-effective with respect to each country’s willingness to pay threshold. The addition of autoantibody testing dominated the no screening strategy. The budget impact of the strategies ranges between 0.001 and 0.025% of annual public healthcare spending.

Conclusion:
The analysed strategies are considered good value for money with potential cost savings in the long term.
Original languageEnglish
Pages (from-to)387-399
Number of pages13
JournalPersonalized Medicine
Volume20
Issue number4
DOIs
Publication statusE-pub ahead of print - 4 Sept 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors.

Fingerprint

Dive into the research topics of 'Cost–effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries'. Together they form a unique fingerprint.

Cite this